

## **NOTIFICATION OF DATE OF 2022 ANNUAL GENERAL MEETING**

MELBOURNE, Australia, 04 October 2022: Dimerix Limited (ASX: DXB) a biopharmaceutical company with Phase 3 clinical studies in inflammatory diseases currently underway, advises that the Company's Annual General Meeting (AGM) will be held on 29 November 2022 at 2:00pm AEDT at Dimerix Limited's office at 425 Smith Street, Fitzroy VIC 3065.

Further to Listing Rules 3.13.1 and 14.3 and the Company Constitution, nominations for election of Directors at the AGM must be received not less than 35 Business Days before the meeting, being no later than 11 October 2022.

Following formalities, Dimerix's CEO and Managing Director, Dr Nina Webster will provide an update to shareholders.

In order to receive electronic communications, shareholders are encouraged to contact the share registry, Automic Group, via the details below:

- Visit: [www.automicgroup.com.au](http://www.automicgroup.com.au)
- Email: [hello@automic.com.au](mailto:hello@automic.com.au)
- Telephone: (Within Australia) 1300 288 664 (Outside Australia) +61 2 9698 5414

For further information, please visit our website at [www.dimerix.com](http://www.dimerix.com) or contact:

Dr Nina Webster  
Dimerix Limited  
Chief Executive Officer & Managing Director  
Tel: +61 1300 813 321  
E: [investor@dimerix.com](mailto:investor@dimerix.com)

Rudi Michelson  
Monsoon Communications  
Tel: +61 3 9620 3333  
Mob: +61 (0)411 402 737  
E: [rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

Follow us on [LinkedIn](#) and [Twitter](#)

*Authorised for lodgement by the Board of the Company*

**—END—**



#### **About Dimerix**

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology

**Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.**

**Dimerix HQ**  
425 Smith St, Fitzroy 3065  
Victoria, Australia  
T. 1300 813 321  
E. [info@dimerix.com](mailto:info@dimerix.com)